Lars Olson

List of Publications by Year
in descending order

72 papers	6,446 citations	134610 34 h-index	100535 70 g-index
73 all docs	73 docs citations	73 times ranked	8702 citing authors

#	Article	IF	Citations
1	Tetrabenazine Mitigates Aberrant Release and Clearance of Dopamine in the Nigrostriatal System, and Alleviates L-DOPA-Induced Dyskinesia in a Mouse Model of Parkinsonâ€™s Disease. Journal of Parkinson's Disease, 2022, , 1-21.	1.5	1
2	Sustained Release GLP-1 Agonist PT320 Delays Disease Progression in a Mouse Model of Parkinsonâ€™s Disease. ACS Pharmacology and Translational Science, 2021, 4, 858-869.	2.5	12
3	Mitochondrial dysfunction in adult midbrain dopamine neurons triggers an early immune response. PLoS Genetics, 2021, 17, e1009822.	1.5	8
4	Neurotrophic and neuroprotective effects of a monomeric GLP-1/GIP/Gcg receptor triagonist in cellular and rodent models of mild traumatic brain injury. Experimental Neurology, 2020, 324, 113113.	2.0	16
5	Genetic Screening of Plasticity Regulating Nogo-Type Signaling Genes in Migraine. Brain Sciences, 2020, 10, 5.	1.1	1
6	Forebrain NgR1 Overexpression Impairs DA Release Suggesting Synergy of Local and Global Synaptic Plasticity Mechanisms. Frontiers in Synaptic Neuroscience, 2020, 12, 545854.	1.3	2
7	Glucagon-like peptide-1 (GLP-1)-based receptor agonists as a treatment for Parkinsonâ€™s disease. Expert Opinion on Investigational Drugs, 2020, 29, 595-602.	1.9	34
8	Voluntary exercise normalizes the proteomic landscape in muscle and brain and improves the phenotype of progeroid mice. Aging Cell, 2019, 18, e13029.	3.0	25
9	Voluntary exercise delays progressive deterioration of markers of metabolism and behavior in a mouse model of Parkinsonâ€™s disease. Brain Research, 2019, 1720, 146301.	1.1	23
10	Release parameters during progressive degeneration of dopamine neurons in a mouse model reveal earlier impairment of spontaneous than forced behaviors. Journal of Neurochemistry, 2019, 150, 56-73.	2.1	9
11	Incretin Mimetics as Rational Candidates for the Treatment of Traumatic Brain Injury. ACS Pharmacology and Translational Science, 2019, 2, 66-91.	2.5	28
12	Delayed Dopamine Dysfunction and Motor Deficits in Female Parkinson Model Mice. International Journal of Molecular Sciences, 2019, 20, 6251.	1.8	17
13	Role of Nogo Receptor-1 for Recovery of Balance, Cognition, and Emotion after Mild Traumatic Brain Injury in Mice. Journal of Neurotrauma, 2019, 36, 1054-1059.	1.7	6
14	Off-Target Effects in Transgenic Mice: Characterization of Dopamine Transporter (DAT)-Cre Transgenic Mouse Lines Exposes Multiple Non-Dopaminergic Neuronal Clusters Available for Selective Targeting within Limbic Neurocircuitry. ENeuro, 2019, 6, ENEURO.0198-19.2019.	0.9	32
15	USING PROTEOMICS TO ELUCIDATE HOW VOLUNTARY EXERCISE COMBATS AGING PHENOTYPES IN MTDNA MUTATOR MICE. Innovation in Aging, 2018, 2, 334-334.	0.0	0
16	A Nogo-Like Signaling Perspective from Birth to Adulthood and in Old Age: Brain Expression Patterns of Ligands, Receptors and Modulators. Frontiers in Molecular Neuroscience, 2018, 11, 42.	1.4	14
17	Myeloperoxidase-immunoreactive cells are significantly increased in brain areas affected by neurodegeneration in Parkinsonâ€™s and Alzheimerâ€™s disease. Cell and Tissue Research, 2017, 369, 445-454.	1.5	79
18	Rat models of spinal cord injury: from pathology to potential therapies. DMM Disease Models and Mechanisms, 2016, 9, 1125-1137.	1.2	265

#	Article	IF	Citations
19	Strong association between glucocerebrosidase mutations and Parkinson's disease in Sweden. Neurobiology of Aging, 2016, 45, 212.e5-212.e11.	1.5	50
20	NgR1: A Tunable Sensor Regulating Memory Formation, Synaptic, and Dendritic Plasticity. Cerebral Cortex, 2016, 26, 1804-1817.	1.6	25
21	Mitochondrial and Ubiquitin Proteasome System Dysfunction in Ageing and Disease: Two Sides of the Same Coin?. International Journal of Molecular Sciences, 2015, 16, 19458-19476.	1.8	90
22	Delayed Imatinib Treatment for Acute Spinal Cord Injury: Functional Recovery and Serum Biomarkers. Journal of Neurotrauma, 2015, 32, 1645-1657.	1.7	16
23	l-Dopa induced dyskinesias in Parkinsonian mice: Disease severity or l-Dopa history. Brain Research, 2015, 1618, 261-269.	1.1	19
24	Dopamine Is Required for the Neural Representation and Control of Movement Vigor. Cell, 2015, 162, 1418-1430.	13.5	241
25	Repositioning imatinib for spinal cord injury. Neural Regeneration Research, 2015, 10, 1591.	1.6	6
26	Interleukin-6 Secretion by Astrocytes Is Dynamically Regulated by PI3K-mTOR-Calcium Signaling. PLoS ONE, 2014, 9, e92649.	1.1	31
27	Response to the report, â€œA re-assessment of treatment with a tyrosine kinase inhibitor (imatinib) on tissue sparing and functional recovery after spinal cord injuryâ€• by Sharp et al.. Experimental Neurology, 2014, 257, 182-185.	2.0	2
28	Maternally transmitted mitochondrial DNA mutations can reduce lifespan. Scientific Reports, 2014, 4, 6569.	1.6	45
29	Combinatory treatments needed for spinal cord injury. Experimental Neurology, 2013, 248, 309-315.	2.0	24
30	Differential Conserted Activity Induced Regulation of Nogo Receptors (1â€“3), LOTUS and Nogo mRNA in Mouse Brain. PLoS ONE, 2013, 8, e60892.	1.1	12
31	Altered dopamine metabolism and increased vulnerability to MPTP in mice with partial deficiency of mitochondrial complex I in dopamine neurons. Human Molecular Genetics, 2012, 21, 1078-1089.	1.4	69
32	Mitofusin 2 is necessary for striatal axonal projections of midbrain dopamine neurons. Human Molecular Genetics, 2012, 21, 4827-4835.	1.4	149
33	Imatinib Enhances Functional Outcome after Spinal Cord Injury. PLoS ONE, 2012, 7, e38760.	1.1	48
34	Impaired mitochondrial transport and Parkin-independent degeneration of respiratory chain-deficient dopamine neurons in vivo. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 12937-12942.	3.3	258
35	Growth factors and cytokines/chemokines as surrogate biomarkers in cerebrospinal fluid and blood for diagnosing Alzheimerâ€™s disease and mild cognitive impairment. Experimental Gerontology, 2010, 45, 41-46.	1.2	57
36	Inhibiting Epidermal Growth Factor Receptor Improves Structural, Locomotor, Sensory, and Bladder Recovery from Experimental Spinal Cord Injury. Journal of Neuroscience, 2007, 27, 6428-6435.	1.7	103

#	Article	IF	Citations
37	Progressive parkinsonism in mice with respiratory-chain-deficient dopamine neurons. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 1325-1330.	3.3	516
38	Blood Oxygenation Level-Dependent Visualization of Synaptic Relay Stations of Sensory Pathways along the Neuroaxis in Response to Graded Sensory Stimulation of a Limb. Journal of Neuroscience, 2006, 26, 6330-6336.	1.7	84
39	Allodynia limits the usefulness of intraspinal neural stem cell grafts; directed differentiation improves outcome. Nature Neuroscience, 2005, 8, 346-353.	7.1	582
40	Partial recovery after treatment of chronic paraplegia in rat. Experimental Neurology, 2004, 188, 33-42.	2.0	24
41	A Spinal Thecal Sac Constriction Model Supports the Theory That Induced Pressure Gradients in the Cord Cause Edema and Cyst Formation. Neurosurgery, 2001, 48, 636-646.	0.6	61
42	NGF, NT-3 and Trk C mRNAs, but not TrkA mRNA, are upregulated in the paraventricular structures in experimental hydrocephalus. Child's Nervous System, 2001, 17, 704-712.	0.6	15
43	GDNF and NGF family members and receptors in human fetal and adult spinal cord and dorsal root ganglia. Journal of Comparative Neurology, 2001, 440, 204-217.	0.9	83
44	GFR?-1 mRNA in dopaminergic and nondopaminergic neurons in the substantia nigra and ventral tegmental area. Journal of Comparative Neurology, 2001, 441, 106-117.	0.9	65
45	Identification of four novel polymorphisms in the calcitonin/Î±-CGRP (CALCA) gene and an investigation of their possible associations with Parkinson disease, schizophrenia, and manic depression. Human Mutation, 2001, 17, 435-436.	1.1	24
46	NURR1 Mutations in cases of schizophrenia and manic-depressive disorder. American Journal of Medical Genetics Part A, 2000, 96, 808-813.	2.4	137
47	Alcohol dehydrogenase alleles in Parkinson's disease. Movement Disorders, 2000, 15, 813-818.	2.2	64
48	Running and cocaine both upregulate dynorphin mRNA in medial caudate putamen. European Journal of Neuroscience, 2000, 12, 2967-2974.	1.2	114
49	Neurturin, RET, GFRÎ±-1 and GFRÎ±-2, but not GFRÎ±-3, mRNA are expressed in mice gonads. Cell and Tissue Research, 2000, 299, 409-415.	1.5	29
50	Role of retinoids in the CNS: differential expression of retinoid binding proteins and receptors and evidence for presence of retinoic acid. European Journal of Neuroscience, 1999, 11, 407-416.	1.2	224
51	Retinoid-X receptor signalling in the developing spinal cord. Nature, 1998, 395, 398-402.	13.7	122
52	Changes in neurotrophin-3 messenger RNA expression patterns in the prenatal rat tongue suggest guidance of developing somatosensory nerves to their final targets. Cell and Tissue Research, 1998, 292, 619-623.	1.5	23
53	GFRÎ±-3, a protein related to GFRÎ±-1, is expressed in developing peripheral neurons and ensheathing cells. European Journal of Neuroscience, 1998, 10, 1508-1517.	1.2	54
54	High-Resolution MRI of Intact and Transected Rat Spinal Cord. Experimental Neurology, 1998, 153, 299-312.	2.0	57

#	Article	IF	Citations
55	NGF, BDNF, NT3, NT4 and GDNF in tooth development. European Journal of Oral Sciences, 1998, 106, 94-99.	0.7	90
56	Spinal Cord Repair Strategies: Problems and Prospects. Journal of Spinal Cord Medicine, 1997, 20, 379-383.	0.7	3
57	Dopamine Neuron Agenesis in Nurr1-Deficient Mice. Science, 1997, 276, 248-250.	6.0	1,026
58	Gait Analysis of Adult Paraplegic Rats after Spinal Cord Repair. Experimental Neurology, 1997, 148, 544-557.	2.0	118
59	Regeneration in the adult central nervous system: Experimental repair strategies. Nature Medicine, 1997, 3, 1329-1335.	15.2	103
60	Downregulation of brain-derived neurotrophic factor mRNA in adult rat brain after acute administration of methylmercury. Molecular and Chemical Neuropathology, 1997, 31, 225-233.	1.0	18
61	Cellular expression of neurotrophin mRNAs during tooth development. Cell and Tissue Research, 1997, 290, 569-580.	1.5	79
62	Cellular and developmental patterns of expression of Ret and glial cell line-derived neurotrophic factor receptor alpha mRNAs. Experimental Brain Research, 1997, 115, 410-422.	0.7	147
63	Cellular expression of GDNF mRNA suggests multiple functions inside and outside the nervous system. Cell and Tissue Research, 1996, 286, 191-207.	1.5	214
64	Differential expression of brain-derived neurotrophic factor and neurotrophin 3 mRNA in lingual papillae and taste buds indicates roles in gustatory and somatosensory innervation. , 1996, 376, 587-602.		109
65	Differential immune responses to fetal intracameral spinal cord and cortex cerebri grafts. Experimental Brain Research, 1996, 110, 223-34.	0.7	3
66	Toward trophic treatment in parkinsonism: A primate step. Nature Medicine, 1996, 2, 400-401.	15.2	17
67	Neuronal and nonneuronal expression of neurotrophins and their receptors in sensory and sympathetic ganglia suggest new intercellular trophic interactions. Journal of Comparative Neurology, 1995, 353, 143-159.	0.9	226
68	Fibrin Glue Used as an Adhesive Agent in CNS Tissues. Journal of Neural Transplantation & Plasticity, 1995, 5, 233-243.	0.7	26
69	Expression of Nerve Growth Factor, Brain-Derived Neurotrophic Factor and Neurotrophin-3 mRNAs in Human Cortical Xenografts. Journal of Neural Transplantation & Plasticity, 1995, 5, 257-264.	0.7	9
70	Locus coeruleus terminals in intraocularly transplanted spinal cords as compared with catecholamine terminals in normal spinal cords: Their synaptic densities and functional considerations. Medical Electron Microscopy: Official Journal of the Clinical Electron Microscopy Society of Japan, 1994, 27, 123-135.	1.8	1
71	Human Fetal Cortical Tissue Fragments Survive Grafting following One Week Storage AT +4Â°C. Cell Transplantation, 1994, 3, 475-479.	1.2	6
72	Functional regeneration of 5-hydroxytryptamine nerve terminals in the rat spinal cord following 5,6-dihydroxytryptamine induced degeneration. Brain Research, 1974, 78, 377-394.	1.1	156